#USA #Los Angeles #Schall Law Firm #Securities Fraud #uniQure N.V.

Schall Law Firm Mobilizes Investors Against uniQure N.V.

A significant opportunity has arisen for investors in uniQure N.V. as the Schall Law Firm, a prominent advocate for shareholder rights, begins efforts on a class action lawsuit against the company. This legal action centers around allegations of securities fraud involving the company's misleading statements and actions during a specified period.

The Context of the Lawsuit

The lawsuit targets uniQure, a biotechnology company known for its pioneering approach to gene therapies. The key focus of this case relates to events occurring between September 24, 2025, and October 31, 2025, during which investors who acquired equities of uniQure may have encountered significant losses due to the purported fraudulent activities of the company.

According to legal representatives, uniQure allegedly violated the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a), as well as Rule 10b-5 as established by the U.S. Securities and Exchange Commission (SEC). The instance at the core of this lawsuit is the company's failure to obtain necessary full FDA approval for its pivotal study, which it failed to transparently communicate to stakeholders, thus impacting their investment decisions.

Claims Made Against uniQure

The claim asserts that uniQure provided false and misleading information regarding its FDA submissions. Investors believed they were investing in a company poised for success, yet it appears that vital information pertaining to delays in its Biologics License Application (BLA) was inadequately disclosed. When these truths surfaced, it led to a decline in the company's stock value, ultimately affecting the financial standing of its investors. Such actions, if proven, signify not only negligence but potentially deliberate attempts to mislead stakeholders.

The Schall Law Firm invites shareholders who purchased stocks during the class period to come forward and join the class action suit. Interested parties are encouraged to contact the firm by April 13, 2026, to discuss their eligibility and rights regarding this case.

Legal Representation Details

For those affected, the Schall Law Firm is available for consultations at no cost. Interested investors can reach out to Brian Schall directly at the firm's Los Angeles office, or visit their website for more information. This representation may open the door for shareholders to reclaim losses stemming from the alleged misconduct.

Moreover, the class in this lawsuit has not yet been certified, highlighting the importance of timely action for interested investors. By participating in this class action, individuals can ensure they are represented in this important legal proceeding that could potentially recover financial losses stemming from uniQure's actions.

Conclusion

As this legal battle unfolds, it serves as a reminder of the importance of transparency and honesty within the financial markets. Investors must remain vigilant and informed about the companies they choose to invest in, recognizing that subpar disclosure can lead to significant financial repercussions. The Schall Law Firm's action on behalf of uniQure's investors emphasizes the need for accountability in the corporate sector, especially in the biotech industry's rapidly evolving landscape.